Trial · NCT07346157
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
NCT07346157, Phase 1, Phase 2, Recruiting, Sabine Mueller, MD, PhD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease. Trials, record NCT07346157. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07346157
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
- NCT number
- NCT07346157
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 69 participants, estimated
- Lead sponsor
- Sabine Mueller, MD, PhD
- Conditions
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
- Interventions
- Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ)
- First posted
- 2026-01-16
- Last updated
- 2026-09-28
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants experienced an Adverse Event | Up to 28 days | Proportion of participants with adverse events of L-T3 as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0) |
| Primary | Proportion of participants who experience dose-limiting toxicity (DLT) (Dose Escalation) | Up to 28 days | The DLT evaluable analysis set includes all participants in the dose-finding part of the study who have received the target doses of L-T3, and who have either experienced a DLT or were followed for the full DLT evaluation period. DLT is defined as L-T3-related toxicity at a frequency ≥33% in any treatment arm. |
| Primary | Maximum Tolerated Dose (MTD) (Dose Escalation) | Up to 28 days | The DLT evaluable analysis set includes all participants in the dose-finding part of the study who have received the target doses of L-T3, and who have either experienced a DLT or were followed for the full DLT evaluation period. The MTD is defined as the dose level given for 14 days which ≤ 1/6 participants experience a DLT. |
| Primary | Percentage Progressive Free Survival (PFS) at month 9 | up to 9 months | Cohort 1 Phase 2, PFS at 9 months is defined as the proportion of patients alive and progression-free 9 months from start of treatment. Any patient lost-to-follow-up prior to 9 months will be considered an event (i.e., progression/death) for the purposes of the analysis. |
| Primary | Percentage of cf-DNA clearance | Up to 30 days after last dose of L-T3. | Participants in Cohort 2 Phase 2 will be assessed in two serial measurements of at least one month apart to determine cf-DNA clearance in cerebrospinal fluid (CSF). Percentage of participants with cf-DNA clearance will be reported. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07346157
GET https://conductscience.org/api/trials/v1/NCT07346157/registered